Abolfazl Olyaei | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Best Researcher Award

Abolfazl Olyaei
Imam Khomeini International University Faculty of Science, Iran
Abolfazl Olyaei
Affiliation Imam Khomeini International University Faculty of Science
Country Iran
Scopus ID 14009290900
Documents 94
Citations 1,047
h-index 18
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event International Forensic Scientist Awards
ORCID 0000-0003-2976-9481

The Best Researcher Award recognizes sustained scholarly achievement and measurable scientific impact within a specialized discipline. This article summarizes the academic profile of Abolfazl Olyaei, whose research activities focus on heterocyclic chemistry, green synthetic methodologies, medicinal chemistry, and pharmaceutical sciences. The information presented is based on publicly available scholarly records, publication metadata, citation indicators, and institutional affiliations.[1]

Abstract

Abolfazl Olyaei has established a consistent research portfolio in synthetic organic chemistry with emphasis on environmentally friendly reaction pathways, heterocyclic compounds, and biologically active molecular frameworks. His publication record demonstrates continuing contributions toward sustainable synthetic methodologies and pharmaceutical chemistry, supported by strong citation performance and international journal publications.[2]

Keywords

Green Chemistry, Heterocyclic Synthesis, Pharmaceutical Science, Organic Chemistry, Medicinal Chemistry, Catalysis, Sustainable Synthesis, Toxicology.

Introduction

Modern pharmaceutical research increasingly emphasizes sustainable chemical synthesis and efficient production of biologically relevant compounds. Dr. Olyaei’s investigations contribute to these objectives by exploring one-pot multicomponent reactions, environmentally benign solvents, and innovative heterocyclic scaffolds applicable to medicinal chemistry.[3]

Research Profile

According to indexed scholarly databases, the researcher has produced 94 publications with more than one thousand citations and an h-index of 18. His academic work spans pharmacology, toxicology, pharmaceutical science, and advanced organic synthesis. Collaborative publications appear in internationally recognized journals including RSC Advances and ChemistrySelect.[1]

Research Contributions

  • Development of green multicomponent synthetic methodologies.
  • Investigation of heterocyclic compounds with pharmaceutical relevance.
  • Promotion of aqueous and environmentally friendly reaction media.
  • Review articles summarizing biologically active molecular frameworks.

Publications

  • Aqueous glyoxal: a versatile synthon in heterocyclic synthesis. RSC Advances (2026).
  • Regioselective green synthesis of indole-substituted benzo[f]chromenes. RSC Advances (2026).
  • Sequential Tandem Four-Component Reaction. ChemistrySelect (2025).
  • Review on synthesis of furonaphthoquinones. RSC Advances (2025).
  • Acid-Mediated One-Pot Three-Component Tandem Cyclization. ChemistrySelect (2024).

Research Impact

The citation profile and publication output indicate sustained scholarly influence in synthetic and medicinal chemistry. Research themes emphasize reproducibility, environmentally responsible synthesis, and development of biologically relevant compounds, reflecting continued engagement with internationally recognized scientific challenges.[4]

Award Suitability

Based on documented publication productivity, citation performance, peer-reviewed contributions, and relevance to pharmaceutical and forensic sciences, the academic profile demonstrates characteristics commonly considered during international research award evaluations. This assessment reflects publicly available scholarly evidence rather than endorsement.[5]

Conclusion

Abolfazl Olyaei has developed a noteworthy academic record through sustained publication, interdisciplinary collaboration, and contributions to green synthetic chemistry. His research continues to support advances in pharmaceutical science and heterocyclic chemistry while maintaining international scholarly visibility through indexed publications and measurable citation impact.

External Links

References

  1. Elsevier. Scopus Author Details: Abolfazl Olyaei, Author ID 14009290900.
    https://www.scopus.com/authid/detail.uri?authorId=14009290900
  2. ORCID. Researcher Profile.
    https://orcid.org/0000-0003-2976-9481
  3. RSC Advances. Aqueous glyoxal: a versatile synthon in heterocyclic synthesis.
    https://doi.org/10.1039/D5RA08496B
  4. ChemistrySelect. Sequential Tandem Four-Component Reaction.
    https://doi.org/10.1002/slct.202505685
  5. International Forensic Scientist Awards. Official Award Website.
    forensicscientist.org

Mohammad El Garhy | Medicine and Health Sciences | Best Innovation Award

Best Innovation Award

Mohammad El Garhy
Researcher Mohammad El Garhy
Affiliation Department of Internal Medicine I, Cardiology, University Hospital Jena
Country Germany
Scopus ID 57192109926
Documents 19
Citations 219
h-index 5
Subject Area Medicine and Health Sciences
Event International Forensic Scientist Awards
ORCID 0000-0002-8578-0135

Mohammad El Garhy
Department of Internal Medicine I, Cardiology, University Hospital Jena, Germany

The Best Innovation Award recognizes scholarly contributions demonstrating scientific originality, translational relevance, and measurable impact within their respective disciplines. Mohammad El Garhy is a cardiology researcher whose academic work emphasizes structural heart disease, transcatheter cardiovascular interventions, multimodality imaging, and minimally invasive diagnostic technologies. His publications reflect continued participation in collaborative clinical research concerning transcatheter valve therapies, cardiovascular imaging, and interventional cardiology, contributing to evidence-based improvements in patient management.[1]

Abstract

Mohammad El Garhy has developed a publication record focused on interventional cardiology, cardiovascular imaging, and catheter-based structural heart interventions. His research addresses clinically important topics including transcatheter aortic valve implantation, MitraClip therapy, computed tomography-based valve assessment, and the expanding role of endoscopic ultrasound in cardiovascular diagnosis. These investigations contribute to improved procedural planning and patient outcomes while supporting innovation in minimally invasive cardiovascular medicine.[2]

Keywords

  • Interventional Cardiology
  • Transcatheter Valve Therapy
  • Cardiovascular Imaging
  • Structural Heart Disease
  • Medical Innovation

Introduction

Advances in structural heart interventions increasingly depend upon precise imaging, multidisciplinary clinical decision-making, and minimally invasive therapeutic strategies. Mohammad El Garhy’s scholarly work aligns with these developments by examining diagnostic technologies and transcatheter procedures that support evidence-based cardiovascular care. His publications have appeared in peer-reviewed journals dedicated to clinical cardiology and cardiovascular interventions.[3]

Research Profile

According to the supplied academic metrics, Mohammad El Garhy has authored 19 indexed publications with 219 citations and an h-index of 5. His primary research interests include transcatheter aortic valve implantation, mitral valve repair, computed tomography assessment of valvular disease, endoscopic ultrasound applications, and cardiovascular intervention planning.[1]

Research Contributions

  • Evaluation of transcatheter mitral valve repair outcomes.
  • Clinical assessment of porcelain aorta during TAVI procedures.
  • Studies comparing CT-based aortic valve calcium quantification methods.
  • Investigation of endoscopic ultrasound for cardiovascular diagnosis and intervention.
  • Clinical analyses supporting minimally invasive structural heart therapies.

Publications

  • The Role of Endoscopic Ultrasound in Cardiology (2026).
  • Impact of Porcelain Aorta on Outcomes in TAVI (2025).
  • Transcatheter Mitral Valve Repair via MitraClip (2023).
  • Contemporary Results of Transcatheter Mitral Valve Procedures (2022).
  • Aortic Valve Calcium Volume Assessment in TAVR Patients (2022).

Research Impact

The available publication record demonstrates continuing engagement in clinically relevant cardiovascular research. Studies addressing procedural optimization, diagnostic imaging, and structural heart interventions provide evidence that may support future improvements in patient care, multidisciplinary practice, and minimally invasive cardiovascular medicine.[4]

Award Suitability

Based on the documented publication record, research metrics, and emphasis on innovative cardiovascular diagnostics and interventions, Mohammad El Garhy’s scholarly activities demonstrate characteristics commonly considered during evaluations for innovation-oriented academic recognition. Award decisions remain dependent upon the official selection criteria established by the organizing committee.[5]

Conclusion

Mohammad El Garhy has contributed to contemporary cardiovascular medicine through investigations involving structural heart disease, catheter-based interventions, and advanced imaging. His research portfolio reflects ongoing participation in clinically significant studies that support evidence generation and innovation within interventional cardiology.

References

  1. Elsevier. Scopus Author Details: Mohammad El Garhy, Author ID 57192109926.
    https://www.scopus.com/authid/detail.uri?authorId=57192109926
  2. El Garhy M. The Role of Endoscopic Ultrasound in Cardiology. Journal of Clinical Medicine (2026). DOI:
    https://doi.org/10.3390/jcm15135006
  3. Open Heart. Impact of Porcelain Aorta on Outcomes in TAVI.
    https://doi.org/10.1136/openhrt-2024-003069
  4. Interventional Cardiology. Transcatheter Mitral Valve Repair via MitraClip.
    https://doi.org/10.15420/icr.2021.28
  5. The Egyptian Heart Journal. Contemporary Results of Transcatheter Mitral Valve Procedures.
    https://doi.org/10.1186/s43044-022-00257-x

Rachael Gakii Murithi | Medicine and Health Sciences | Innovative Research Award

Innovative Research Award

Rachael Gakii Murithi
Tsinghua University, China

Rachael Gakii Murithi
Affiliation Tsinghua University
Country China
Scopus ID 57221382349
Documents 5
Citations 73
h-index 5
Subject Area Medicine and Health Sciences
Event International Forensic Scientist Awards
ORCID 0000-0002-6653-3833

The Innovative Research Award recognizes the scholarly contributions of Rachael Gakii Murithi in the interdisciplinary fields of public health, maternal survival studies, environmental exposure analysis, and global health inequality research. Her academic work at Tsinghua University reflects a research-oriented approach focused on evidence-based health analysis, comparative international studies, and systematic reviews addressing vulnerable populations. Her publications contribute to contemporary discourse surrounding maternal mortality, gender inequality, indoor pollution exposure, and health disparities in low- and middle-income countries.[1]

Abstract

Rachael Gakii Murithi has contributed to emerging research discussions within medicine and health sciences through publications examining maternal mortality, environmental pollutants, gender inequality, and adolescent fertility indicators. Her scholarly output integrates quantitative health analysis with comparative global datasets to evaluate structural determinants influencing health outcomes across developing regions.[2]

Keywords

Maternal mortality, global health inequality, adolescent fertility, indoor pollutants, neurodevelopmental disorders, environmental health, public health analytics, comparative health studies.

Introduction

Contemporary health science increasingly emphasizes interdisciplinary methodologies to address inequalities in healthcare access and population health outcomes. Murithi’s work contributes to this framework by examining maternal survival disparities, exposure to airborne pollutants, and sociopolitical determinants of gender inequality across multiple regions.[3] Her studies utilize comparative analyses, systematic review methods, and public health indicators to interpret global health trends.

Research Profile

Murithi’s academic profile includes publications indexed through recognized scholarly databases and citation platforms. Her research interests focus on maternal health, environmental risk assessment, adolescent fertility patterns, and social determinants affecting vulnerable populations. The integration of statistical modeling with comparative international data has enabled her work to address multidimensional public health concerns.[4]

Research Contributions

  • Conducted comparative cluster analyses examining maternal survival inequalities across 49 Sub-Saharan African countries.
  • Investigated adolescent birth rates and female education as determinants of maternal mortality disparities in low- and middle-income countries.
  • Published systematic reviews on indoor pollutants and their association with respiratory, neurodevelopmental, and oncological risks.
  • Explored structural drivers of gender inequality, including fertility patterns and political representation.

Publications

  • Inequality and maternal survival cluster analysis of 49 Sub Saharan countries (2026).
  • Plastic mulching drives microplastic accumulation and redistribution in arid agroecosystems (2026).
  • Adolescent Birth Rates and Female Education Drive Maternal Mortality Disparities in Low- and Middle-Income Countries (2026).

Research Impact

Murithi’s research output has contributed to scholarly discussions surrounding public health inequality and environmental health exposure. Citation metrics indicate academic engagement with her work in areas related to maternal health and environmental risk analysis. Her studies also support policy-oriented discussions concerning education, reproductive health, and pollution-related health outcomes in vulnerable populations.[5]

Award Suitability

The Innovative Research Award acknowledges scholarly contributions demonstrating interdisciplinary relevance, methodological rigor, and measurable academic impact. Murithi’s research portfolio aligns with these criteria through investigations addressing global maternal health disparities, environmental exposure risks, and gender-related public health indicators. Her work reflects ongoing engagement with contemporary healthcare challenges and data-driven research methodologies.[6]

Conclusion

Rachael Gakii Murithi’s academic contributions within medicine and health sciences demonstrate a sustained focus on global health inequality, environmental exposure analysis, and maternal survival research. Through comparative studies, systematic reviews, and interdisciplinary public health investigations, her work contributes to evidence-based understanding of health disparities affecting diverse populations worldwide.

References

  1. Elsevier. (n.d.). Scopus author details: Rachael Gakii Murithi, Author ID 57221382349. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57221382349
  2. Murithi, R. G. (2026). Inequality and maternal survival cluster analysis of 49 Sub Saharan countries. Discover Public Health.
    https://doi.org/10.1186/s12982-026-02069-9
  3. Murithi, R. G. (2026). Adolescent Birth Rates and Female Education Drive Maternal Mortality Disparities in Low- and Middle-Income Countries.
    https://doi.org/10.33140/japm.11.01.01
  4. Murithi, R. G. (2025). Prenatal Exposure to Airborne and Indoor Pollutants and the Risk of Childhood Neurodevelopmental Disorders.
    https://doi.org/10.33140/japm.10.03.02
  5. Murithi, R. G. (2025). Associations between Indoor Pollutants, Neurodevelopmental, Oncological, and Respiratory Health Risks, and Vulnerable Populations: A Systematic Review.
    https://doi.org/10.21203/rs.3.rs-7440867/v1
  6. International Forensic Scientist Awards. (n.d.). Award recognition and academic excellence platform.
    forensicscientist.org

Yury Kustov | Medicine and Health Sciences | Best Researcher Award

Best Researcher Award

Yury Kustov
Peoples’ Friendship University of Russia
Yury Kustov
Affiliation Peoples’ Friendship University of Russia
Country Russia
Scopus ID 58987836800
Documents 5
Citations 4
h-index 1
Subject Area Medicine and Health Sciences
Event International Forensic Scientist Awards
ORCID 0009-0002-4859-4322

Yury Kustov is a researcher affiliated with the Peoples’ Friendship University of Russia whose scholarly work focuses on medicine, pharmacovigilance, drug safety, pulmonary fibrosis, and clinical pharmacology. His recent publications examine adverse drug reactions, pediatric pharmacotherapy, pulmonary complications, and systematic reviews related to pharmacokinetics and post-COVID-19 outcomes. Through contributions indexed in Scopus, Kustov has participated in interdisciplinary investigations concerning patient safety and evidence-based medical analysis.[1] His profile reflects active engagement in healthcare-related research areas associated with pharmacological monitoring and clinical risk assessment.[2]

Abstract

The academic contributions of Yury Kustov are associated with contemporary clinical medicine and pharmacovigilance research. His published studies explore adverse drug reactions, pulmonary fibrosis, antibiotic safety, and pediatric therapeutic outcomes. Several investigations emphasize spontaneous report database analysis and systematic reviews in order to improve healthcare monitoring and pharmacological safety standards.[3] These contributions support broader scientific discussions regarding medication-related complications and patient-centered clinical evaluation.

Keywords

Pharmacovigilance, Clinical Pharmacology, Pulmonary Fibrosis, Pediatric Medicine, Drug Safety, Post-COVID Research, Pharmacokinetics, Medicine and Health Sciences.

Introduction

The advancement of modern healthcare increasingly depends on pharmacological safety assessment and evidence-based therapeutic monitoring. Researchers involved in pharmacovigilance contribute to the identification of adverse reactions and clinical complications linked to pharmaceutical interventions. Yury Kustov has participated in this research landscape through studies addressing antibacterial drug reactions, pulmonary fibrosis, and pediatric medicine.[4] His publications demonstrate engagement with healthcare datasets and clinical literature reviews that contribute to scientific understanding of treatment-related risks.

Research Profile

Kustov’s academic profile includes journal articles and conference publications indexed through Scopus and related scholarly databases. His research areas include pharmacokinetics in chronic heart failure, pulmonary fibrosis associated with pharmacotherapy, and pediatric antibacterial drug safety. The researcher has also examined Stevens–Johnson syndrome and toxic epidermal necrolysis using spontaneous reporting systems.[5] These studies align with medical efforts to improve treatment evaluation and patient safety methodologies.

Research Contributions

  • Analysis of fluoroquinolone safety in pediatric populations through pharmacovigilance database studies.
  • Systematic review research concerning pharmacokinetic alterations in chronic heart failure patients.
  • Investigations into pulmonary fibrosis and post-COVID-19 pharmacotherapy outcomes.
  • Evaluation of spontaneous adverse drug reaction reports linked to antibacterial medications.

Publications

  • “Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis”
  • “Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review”
  • “Drug-Induced Pulmonary Fibrosis: National Database Analysis”

Research Impact

The research contributions of Yury Kustov demonstrate relevance to healthcare monitoring, medication safety assessment, and evidence-based pharmacology. By utilizing systematic reviews and spontaneous report analyses, his studies contribute to discussions surrounding adverse drug reaction surveillance and therapeutic evaluation. Such research supports clinicians, pharmacologists, and healthcare researchers seeking to understand treatment-related complications in vulnerable patient populations.

Award Suitability

Yury Kustov’s publication record and involvement in pharmacovigilance-related medical studies align with the objectives of the International Forensic Scientist Awards. His focus on drug safety analysis, pulmonary complications, and healthcare risk assessment reflects scholarly engagement with medically significant challenges. The integration of database-driven clinical analysis and systematic review methodologies further demonstrates research activity associated with modern healthcare science and patient protection initiatives.

Conclusion

Yury Kustov has contributed to medicine and health sciences through publications examining pharmacovigilance, pulmonary fibrosis, clinical pharmacology, and pediatric drug safety. His academic profile reflects ongoing participation in evidence-based medical research and healthcare monitoring studies. Through indexed scholarly outputs and DOI-linked publications, his work contributes to the broader scientific understanding of pharmaceutical safety and patient-centered clinical investigation.

References

  1. Elsevier. (n.d.). Scopus author details: Yury Kustov, Author ID 58987836800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58987836800
  2. ORCID. (n.d.). Yury Kustov ORCID profile.
    https://orcid.org/0009-0002-4859-4322
  3. Kustov, Y. (2026). Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis.
    https://doi.org/10.1177/09246479251398995
  4. Kustov, Y. (2025). Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review.
    https://doi.org/10.3390/ijms26199495
  5. Kustov, Y. (2024). Drug-Induced Pulmonary Fibrosis: National Database Analysis.
    https://doi.org/10.3390/biomedicines12122650

Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Dr. Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Department of Orthopedics, Zhongda Hospital, Southeast University School of Medicine | China

Dr. Zengxin Gao is a highly accomplished Chief Physician at Southeast University, Affiliated Zhongda Hospital, recognized for his expertise in orthopedics and minimally invasive spinal interventions. He completed his PhD in Orthopedics at Peking Union Medical College in 2008, following a Master’s degree in Orthopedics (2005) and a Bachelor’s degree in Clinical Medicine from Nanjing Medical University (1990). Dr. Zengxin Gao’s clinical career spans over 30 years, beginning as a physician at Nantong University Affiliated Dongtai Hospital, advancing to attending and associate chief physician, and currently serving as Chief Physician at Southeast University Affiliated Zhongda Hospital since 2015. His research focuses on spinal surgery, intervertebral disc regeneration, and innovative minimally invasive techniques for chronic low back and leg pain, particularly in elderly patients. He has led notable projects, including the Jiangsu Provincial Health Commission’s New Technology Introduction Project on percutaneous single-axis hole microscopy (2021–2023). Dr. Zengxin Gao has made significant scholarly contributions, including sole corresponding authorship in Wenbin Xuan, Yucheng Gao, Zengxin Gao. Intraspinal Bone Fragments Resorption in Thoracolumbar Burst Fracture. JAMA Neurol. 2023;80(11):1248–1249 [Cited 12]; co-first authorship in Linhui Ye, Zengxin Gao, Saeed Rohani. Intervertebral disk regeneration in a rat model by allopurinol-loaded Chitosan/alginate hydrogel. Biomol Biomed. 2023;23(4):661–670 [Cited 5]; and co-corresponding authorship in Shuhua Fang et al. Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskelet Disord. 2024;25:5 [Cited 3]. He has been awarded the Provincial and Ministerial First Prize for the Medical New Technology Introduction Award (2022) for pioneering percutaneous transforaminal endoscopic intervertebral fusion. Dr. Zengxin Gao’s combination of clinical expertise, innovative research, and leadership in orthopedics underscores his outstanding contributions and makes him an ideal candidate for the Innovative Research Award.

Profile: Scopus

Featured Publications

• Xuan, W., Gao, Y., & Gao, Z. (2023). Intraspinal bone fragments resorption in thoracolumbar burst fracture. JAMA Neurology, 80(11), 1248–1249.
https://doi.org/10.1001/jamaneurol.2023.2901

• Ye, L., Gao, Z., & Rohani, S. (2023). Intervertebral disk regeneration in a rat model by allopurinol-loaded chitosan/alginate hydrogel. Biomolecules and Biomedicine, 23(4), 661–670.
https://doi.org/10.17305/bjbms.2023.8535

• Fang, S., Cao, D., Wu, Z., Chen, J., Huang, Y., Shen, Y., & Gao, Z. (2024). Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskeletal Disorders, 25(1), 5.
https://doi.org/10.1186/s12891-023-07172-0

• Gao, Z., Lin, Y., Wu, Z., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2020). LncRNA SNHG6 can regulate the proliferation and apoptosis of rat degenerate nucleus pulposus cells via regulating the expression of miR-101-3p. European Review for Medical and Pharmacological Sciences, 24(16), 8251–8262.
https://doi.org/10.26355/eurrev_202008_22592

• Gao, Z., Lin, Y., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2019). Sinomenine ameliorates intervertebral disc degeneration via inhibition of apoptosis and autophagy in vitro and in vivo. American Journal of Translational Research, 11(9), 5956–5966.
https://www.ajtr.org/files/ajtr0094769.pdf

Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Prof. Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Wannan Medical College | China

Prof. Zhiliang Xu, affiliated with Wannan Medical College, Wuhu, China, is a distinguished molecular biologist and epigenetics researcher whose work focuses on histone ubiquitination, chromatin remodeling, and their implications in neurological disorders, cancer, gametogenesis, and cellular reprogramming. He earned his Ph.D. from the State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences in 2017. According to Scopus, Prof. Zhiliang Xu has authored 11 publications, which have been cited 34 times, and he holds an h-index of 4, demonstrating the impact of his research in the scientific community. His seminal studies elucidated the role of H2B ubiquitination in chromatin relaxation during meiosis and cellular reprogramming, published in journals such as Nucleic Acids Research (2016), Cell Proliferation (2021), and Reproduction (2017). His recent work on neuronal repair, gut-liver axis regulation in diabetes, and genomic approaches to thalassemia has been featured in FASEB Journal (2025), Annals of Hematology (2025), and Neuroscience Letters (2025). Prof. Zhiliang Xu leads multiple high-impact national and provincial research projects, serves as a peer reviewer for journals including Scientific Reports and Neurochemical Research, and evaluates theses for graduate and doctoral candidates. Recognized with the 2021 National Maternal and Child Health Science and Technology Award (First Prize), the 2022 Guangzhou High-level Talent Award, and the 2024 Outstanding Young Talent honor in Anhui Province, Prof. Zhiliang Xu continues to advance fundamental understanding of chromatin biology and epigenetic regulation, exemplifying excellence, mentorship, and translational scientific impact, making him an outstanding candidate for the Best Researcher Award.

Profile: Scopus | ORCID

Featured Publications

1. Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025). Beyond transfusions and transplants: Genomic innovations rewriting the narrative of thalassemia. Annals of Hematology.

2. Zhang, Y., Wang, J., Huang, S., Liu, M., Zhao, Y., Xu, Z., & Zhu, X. (2025). Electroacupuncture preconditioning alleviates cortical neuronal injury in cerebral ischemia-reperfusion by rebalancing HES1 and NF-ÎşB expression. Neuroreport.

3. Yan, X., Shi, L., Zhu, X., Zhao, J., Zhao, Y., Luo, J., Li, Q., & Xu, Z. (2025). From microbial homeostasis to systemic pathogenesis: A narrative review on gut flora’s role in neuropsychiatric, metabolic, and cancer disorders. Journal of Inflammation Research.

4. Huang, S., Lu, Y., Fang, W., Huang, Y., Li, Q., & Xu, Z. (2025). Neurodegenerative diseases and neuroinflammation-induced apoptosis. Open Life Sciences.

5. Li, Q., Zhang, L., Sun, Y., Du, Z., Xu, S., Wang, X., Wei, S., Tao, Y., Li, B., Jiang, J., Di, G., Huang, Y., & Xu, Z. (2025). p53 modulates the gut-liver axis via PI3K/AKT/Wnt signaling pathways in type 2 diabetes. FASEB Journal.

6. Li, Q., Yan, X., Zhao, Y., Xu, Z., & Zhu, X. (2025). Paeonol mitigates chronic stress-induced amygdalar neuronal damage through glycogen synthase kinase-3β/calcineurin axis regulation of synaptic plasticity. Neuroreport.

7. Zhu, X., Zhang, Y., Yan, X., Zhao, Y., Shi, L., Sun, Z., Meng, K., Zong, Y., Li, Q., & Xu, Z. (2025). Paeonol facilitates the repair of neuronal damage in the mPFC caused by chronic stress via the Rho GTPases-cofilin1 signaling pathway. Neuroscience Letters, 138329.

Yan Bai | Medicine and Health Sciences | Best Researcher Award

Dr. Yan Bai | Medicine and Health Sciences | Best Researcher Award

Yunnan University | China

Dr. Yan Bai is a highly accomplished postdoctoral researcher at the State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan and the Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China. She earned her PhD in Cell Biology from Yunnan University, MSc in Pharmacology from the Chinese PLA Medical Academy, and BSc in Pharmacy from Dali University, establishing a strong interdisciplinary foundation spanning pharmacology, microbiology, and cellular biology. Prior to her current role, she conducted research at the Chinese PLA General Hospital, focusing on combination therapies against multidrug-resistant bacteria. Her research primarily investigates mitochondrial homeostasis, tumor biology, and the molecular mechanisms underlying mitochondrial genetic diseases, with particular attention to mitochondria-associated condensates (MATOs) as regulators of protein translation and mitochondrial integrity. Dr. Yan Bai has led and contributed to several major research projects, including grants from the National Natural Science Foundation of China, the National Basic Research Program, and Yunnan Province Science and Technology initiatives. Her work has resulted in high-impact publications in journals such as Nature Aging (2025), Sci China Life Sci (2025), EMBO J (2024), and Biophys Rep (2024). According to Scopus, she has authored 10 publications, cited 177 times across 169 documents, with an h-index of 6, demonstrating both productivity and influence in her field. Through her interdisciplinary collaborations, innovative experimental approaches, and groundbreaking findings on mitochondrial regulation and aging, Dr. Yan Bai has made significant contributions to biomedical science, advancing understanding of mitochondrial biology, disease mechanisms, and translational biomedical applications.

Profile: Scopus

Featured Publications

Bai, Y., Ma, T., Zhao, S., Li, S., Wang, X., Li, J., Sun, W., Yang, Y., Liu, F., Shan, Q., Qin, Z., Liu, N., Zhang, J., Tian, F., Duan, M., Chen, S., Lai, F., Chen, Q., Wu, X., & Yang, C. (2025). Mitochondria-associated condensates maintain mitochondrial homeostasis and promote lifespan. Nature Aging.

Hao, Q., Bai, Y., Guan, R., Dong, R., Bai, W., Hamdy, H., Wang, L., Meng, M., Sun, Y., Shen, J., & Sun, J. (2025). VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis. Science China Life Sciences, 68(7), 1996–2009.

Hao, Q., Dong, R., Bai, W., Chang, D., Yao, X., Zhang, Y., Xu, H., Li, H., Kui, X., Wang, F., Wang, Y., Wang, C., Lei, Y., Chen, Y., Shen, J., Sang, L., Bai, Y., & Sun, J. (2024). Screening for metastasis-related genes in mouse melanoma cells through sequential tail vein injection. Biophysical Reports, 10(1), 15–21.

Liu, F., Li, T., Gong, H., Tian, F., Bai, Y., Wang, H., Yang, C., Li, Y., Guo, F., Liu, S., & Chen, Q. (2024). Structural insights into the molecular effects of the anthelmintics monepantel and betaine on the Caenorhabditis elegans acetylcholine receptor ACR-23. EMBO Journal, 43(17), 3787–3806.

Wang, T., Zhou, X., Bai, Y., Zhang, L., Li, L., & Wu, C. (2018). Antiepileptic effect of uridine may be caused by regulating dopamine release and receptor expression in corpus striatum. Brain Research, 1688, 47–53.

Bai, Y., Liu, B., Wang, T., Cai, Y., Liang, B., Wang, R., Liu, Y., & Wang, J. (2015). In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 59(3), 1466–1471.

Liu, B., Bai, Y., Liu, Y., Di, X., Zhang, X., Wang, R., & Wang, J. (2015). In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Journal of Chemotherapy, 27(5), 271–276.

Zhongzhen Su | Medicine | Best Researcher Award

Dr. Zhongzhen Su | Medicine | Best Researcher Award

The Fifth Affiliated Hospital of Sun Yat-sen University |China

Dr. Zhongzhen Su is a renowned medical professional with over two decades of expertise in abdominal ultrasound diagnosis and liver cancer interventional therapy. Currently serving as the Director of the Ultrasound Medicine Department at the Fifth Affiliated Hospital of Sun Yat-sen University, he has made pivotal contributions in early liver cancer detection and fibrosis assessment. Recognized as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, Dr. Su has significantly enhanced survival outcomes for cirrhotic patients through innovative imaging techniques.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Established Academic and Research Record:

    • 48 SCI publications with an H-index of 28 and 1,000+ citations, indicating consistent and influential contributions.

    • Highest publication impact factor of 14.3, demonstrating recognition in high-quality journals.

  2. Innovative Contributions:

    • Two patents (e.g., tumor ultrasound phantom, fibrosis prediction model) and innovative developments in liver cancer diagnostics and ablation.

    • Led 18 completed and 1 ongoing research projects, including National Natural Science Foundation grants.

  3. Clinical and Educational Impact:

    • Pioneered early detection and ultrasound-guided treatment of liver cancer, improving survival rates.

    • Trained over 50 postgraduates, indicating a significant contribution to academic mentorship.

  4. Recognitions and Leadership:

    • Recognized as a “High-level Talent in Zhuhai” and “Guangdong Outstanding Young Medical Talent”.

    • Serves as Director of Ultrasound Medicine and holds leadership roles in national professional associations.

  5. Interdisciplinary and AI Integration:

    • Engaged in AI-based fibrosis assessment and multicenter collaborations, showcasing forward-looking research alignment.

🎓 Education

Dr. Zhongzhen Su earned his Ph.D. in Imaging and Nuclear Medicine from Sun Yat-sen University, one of China’s top medical institutions. His academic foundation combines clinical depth with scientific rigor, forming the bedrock for his ongoing advancements in ultrasound-guided interventions and diagnostic radiology.

👨‍⚕️ Experience

With over 20 years of clinical and academic experience, Dr. Zhongzhen Su has held key roles, including Deputy Dean of the Fifth Affiliated Hospital and now Director of Ultrasound Medicine. His leadership has been instrumental in establishing state-of-the-art interventional ultrasound programs, supervising over 50 postgraduates, and leading multicenter clinical trials focused on liver health.

🔬 Research Interest On Medicine

Dr. Zhongzhen Su primary research interests lie in abdominal ultrasound diagnosis, interventional ultrasound for liver cancer, quantitative assessment of liver fibrosis, and post-ablation evaluation techniques. He is also exploring AI-based models for early-stage fibrosis and cancer detection, which promise transformative impacts in personalized medicine.

🏆 Awards

Dr. Zhongzhen Su is a three-time recipient of the Guangdong Science and Technology Awards 🏅, reflecting his leadership in ultrasound-guided interventional innovation. He has also been honored as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, distinctions reserved for top-tier professionals in the region’s medical community.

📚 Publications

1. Nomogram Using Bi-modal Imaging for Predicting Low-level HER2 Expression Status in Breast Cancer

  • Authors: Xingyu Liang, Jiamin Chen, Jiawei Tian, Xin Wen

  • Journal: European Journal of Radiology

  • Year: 2025

2. Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

  • Authors: Yu Li, Sheng Li, Qing Li, Lingling Li, Jianhua Zhou

  • Journal: Korean Journal of Radiology

  • Year: 2025

  • Citations: 0​

3. Doppler Ultrasound Imaging and Shear Wave Elastography for Evaluation of Interstitial Fibrosis/Tubular Atrophy in IgA Nephropathy

  • Authors: Jiaxin Chen, Shuqing Wang, Qunyan Wu, Zhongzhen Su, Yuhong Lin

  • Journal: Abdominal Radiology

  • Year: 2025

4. Tertiary Lymphoid Structure Formation Induced by LIGHT-Engineered and Photosensitive Nanoparticles-Decorated Bacteria Enhances Immune Response Against Colorectal Cancer

  • Authors: Lijun Hu, Li Tan, Shaohui Deng, Honglin Gao, Yujie Jiang, Chen Qiu, Hui Chen, Zecong Xiao, Xintao Shuai, Zhongzhen Su

  • Journal: Biomaterials

  • Year: 2025

  • Citations: 6​

5. Histopathological Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma: Is It Reliable?

  • Authors: Liujun Li, Chaoqun Wu, Feile Ye, Zhou Xuan, Xiaoli Zhang, Jianping Li, Jia Zhou, Zhongzhen Su

  • Journal: World Journal of Gastroenterology

  • Year: 2025

6. Radiomics Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma Using 3D Ultrasound and Whole-Slide Image Fusion

  • Authors: Liujun Li, Shaodong Wang, Jiaxin Chen, Yao Lu, Zhongzhen Su

  • Journal: Small Methods

  • Year: 2025

7. Model Based on Ultrasound and Clinicopathological Characteristics for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

  • Authors: Xin Wen, Jiamin Chen, Jing Zhong, Yuhong Lin, Zhongzhen Su

  • Journal: Quantitative Imaging in Medicine and Surgery

  • Year: 2024

  • Citations: 1​

8. Development and Validation of an Individualized Nomogram for Predicting Patent Foramen Ovale-Associated Stroke: Patent Foramen Ovale Morphology-Based Analysis

  • Authors: Qin Zhang, Mochao Xiao, Wuzhu Lu, Zhongzhen Su, Xiaobo Chen

  • Journal: Echocardiography

  • Year: 2024

đź§ľ Conclusion

In summary, Dr. Zhongzhen Su stands out as a visionary ultrasound expert and medical educator, having redefined interventional standards in liver cancer therapy and fibrosis evaluation. His trailblazing research, prolific publication record, and dedication to clinical excellence make him an ideal nominee for the Best Researcher Award at the FORENSIC SCIENTIST AWARDS. 🏅🔍